STOCK TITAN

Inspira Technologies Oxy Bhn Ltd - IINN STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.

Inspira Technologies Oxy BHN Ltd (IINN) delivers innovative respiratory care solutions through its non-invasive INSPIRA ART system and HYLA blood monitoring technology. This page provides investors and healthcare professionals with essential updates on regulatory milestones, product developments, and clinical partnerships shaping the future of critical care.

Access real-time information on FDA clearances, technology evaluations, and strategic collaborations. Our curated news ensures you stay informed about advancements in extracorporeal oxygenation and AI-driven blood analytics without speculative commentary.

Discover updates across key categories including regulatory submissions, clinical trial results, product launches, and global distribution agreements. All content is verified for accuracy and relevance to support informed decision-making.

Bookmark this page for streamlined access to Inspira Technologies' progress in redefining respiratory support systems. Check back regularly for authoritative reporting on innovations addressing acute respiratory failure and ICU resource challenges.

Rhea-AI Summary
Inspira Technologies unveils INSPIRA ART line at ELSO Conference, including INSPIRA ART100 and ART500 devices. INSPIRA ART500 offers potential breakthrough treatment for severe breathing problems. INSPIRA ART100 estimated to receive FDA clearance in H1 2024. Collaboration with Perfusion Solution for U.S. availability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
none
-
Rhea-AI Summary
Inspira Technologies submits INSPIRA ART 100 to FDA, expects clearance in first half of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. announces financial results for Q2 2023. The company had $8.9 million in cash, cash equivalents, and short-term bank deposits as of June 30, 2023. The INSPIRA ART100 is planned for submission to the FDA for clearance. The INSPIRA ART500 is being developed with integrated AI and blood sensor technology. The net loss for the six months ended June 30, 2023, was $5.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
Rhea-AI Summary
Inspira Technologies completes Usability Study for INSPIRA ART100 device
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
-
Rhea-AI Summary
Inspira Technologies has received ISO 13485:2016 Standard Certification, a requirement for EU regulatory approval. The certification demonstrates adherence to the highest quality management standards in the medical device industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
Rhea-AI Summary
Inspira Technologies, a company aiming to revolutionize acute respiratory care, has released its latest investor deck. The deck highlights their vision, achievements, and projected targets for the second half of 2023. It showcases their cutting-edge extracorporeal blood circulation medical devices, including the INSPIRA™ ART500, which is designed to provide respiratory support without the need for mechanical ventilators. The deck also emphasizes the market potential of the company, with an estimated $20 billion total addressable market for their technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
Inspira Technologies Oxy Bhn Ltd

Nasdaq:IINN

IINN Rankings

IINN Stock Data

15.02M
24.59M
4.01%
4.55%
0.61%
Medical Devices
Healthcare
Link
Israel
Ra'anana